Suchergebnisse - "Exemestane"

PubPharm (13)

1

Updates in hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer in 2021

enthalten in: Bulletin du cancer | 2022

von Mezni, E. | Sabatier, R. | Goncalves, A. | +1

2

Endocrine adjuvant treatment specific features for young breast cancer women

enthalten in: Bulletin du cancer | 2019

von Petit, T.

3

Hormonotherapy for breast cancer prevention : What about women with genetic predisposition to breast cancer?

enthalten in: Bulletin du cancer | 2016

von Sénéchal, C. | Reyal, F. | Callet, N. | +4

4

New options in adjuvant endocrine therapy in breast cancer

enthalten in: Bulletin du cancer | 2016

von Saltel-Fulero, A. | Donnadieu, A. | Leman-Detours, S. | +1

5

Exemestane-everolimus in HER2-negative, hormonal receptor-positive, post-menopausal metastatic breast cancer with resistance to non-steroidal aromatase inhibitor : a new option

enthalten in: Bulletin du cancer | 2014

von Gilabert, M. | Launay, S. | Gonçalves, A.

6

Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women : pharmacological and clinical aspects

enthalten in: Bulletin du cancer | 2004

von de Cremoux, P. | Diéras, V. | Poupon, M. | +4

7

Aromatase inhibitors in adjuvant setting in breast cancer

enthalten in: Bulletin du cancer | 2004

von Spano, J. | Khayat, D. | Delozier, T.

8

Neoadjuvant endocrine therapy for breast cancer : an overview

enthalten in: Bulletin du cancer | 2004

von Domont, J. | Namer, M. | Khayat, D. | +1

9

Aromatase inhibitors : pharmacological aspects

enthalten in: Bulletin du cancer | 2000

von de Crémoux, P.

10

Preclinical evaluation of aromatase inhibitors antitumor activity

enthalten in: Bulletin du cancer | 2000

von Auvray, P. | Bichat, F. | Genne, P.